Immune modulation for cancer therapy

Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that reg...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2014-12, Vol.111 (12), p.2214-2219
Main Authors: NAIDOO, J, PAGE, D. B, WOLCHOK, J. D
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Biological and medical sciences
Cancer therapies
Cell death
Cytotoxicity
Drug dosages
Humans
Immunoglobulins
Immunotherapy
Immunotherapy - methods
Ligands
Lymphocytes
Medical sciences
Melanoma
Metastasis
Minireview
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - immunology
Neoplasms - therapy
Peptides
Proteins
Tumor necrosis factor-TNF
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3
cites cdi_FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3
container_end_page 2219
container_issue 12
container_start_page 2214
container_title British journal of cancer
container_volume 111
creator NAIDOO, J
PAGE, D. B
WOLCHOK, J. D
description Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.
doi_str_mv 10.1038/bjc.2014.348
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4264429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1727687586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3</originalsourceid><addsrcrecordid>eNqF0c9L5DAUB_Agis6qN8_LgCvswY4vv5vLgsi6CoIXPYc0fV07tM2YtIL_vRkcddeLpxDy4cvL-xJyRGFBgZdn1dIvGFCx4KLcIjMqOStoyfQ2mQGALsAw2CPfUlrmq4FS75I9JhmlStEZ-XHd99OA8z7UU-fGNgzzJsS5d4PHOB8fMLrV8wHZaVyX8HBz7pP7y993F1fFze2f64vzm8JLIcdCNAaQI69dUysHqF3dVJ5hLVCWyikGuuHAvEbuhVFS6gqE5xxrI4STFd8nv15zV1PVY-1xGKPr7Cq2vYvPNrjW_v8ytA_2b3iygikhmMkBPzcBMTxOmEbbt8lj17kBw5Qs1UyrUudpvqaKSwABYk2PP9FlmOKQN5GVULoUICGr01flY0gpYvM-NwW7bsrmpuy6KZubyvz7v399x2_VZHCyAS551zUxV9KmD2fAcGMofwG4ApqA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1646784050</pqid></control><display><type>article</type><title>Immune modulation for cancer therapy</title><source>PubMed Central</source><creator>NAIDOO, J ; PAGE, D. B ; WOLCHOK, J. D</creator><creatorcontrib>NAIDOO, J ; PAGE, D. B ; WOLCHOK, J. D</creatorcontrib><description>Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2014.348</identifier><identifier>PMID: 25211661</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Antibodies ; Antigens ; Biological and medical sciences ; Cancer therapies ; Cell death ; Cytotoxicity ; Drug dosages ; Humans ; Immunoglobulins ; Immunotherapy ; Immunotherapy - methods ; Ligands ; Lymphocytes ; Medical sciences ; Melanoma ; Metastasis ; Minireview ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasms - immunology ; Neoplasms - therapy ; Peptides ; Proteins ; Tumor necrosis factor-TNF ; Tumors ; Vaccines</subject><ispartof>British journal of cancer, 2014-12, Vol.111 (12), p.2214-2219</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Dec 9, 2014</rights><rights>Copyright © 2014 Cancer Research UK 2014 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3</citedby><cites>FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=29093991$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25211661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NAIDOO, J</creatorcontrib><creatorcontrib>PAGE, D. B</creatorcontrib><creatorcontrib>WOLCHOK, J. D</creatorcontrib><title>Immune modulation for cancer therapy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Biological and medical sciences</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Minireview</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqF0c9L5DAUB_Agis6qN8_LgCvswY4vv5vLgsi6CoIXPYc0fV07tM2YtIL_vRkcddeLpxDy4cvL-xJyRGFBgZdn1dIvGFCx4KLcIjMqOStoyfQ2mQGALsAw2CPfUlrmq4FS75I9JhmlStEZ-XHd99OA8z7UU-fGNgzzJsS5d4PHOB8fMLrV8wHZaVyX8HBz7pP7y993F1fFze2f64vzm8JLIcdCNAaQI69dUysHqF3dVJ5hLVCWyikGuuHAvEbuhVFS6gqE5xxrI4STFd8nv15zV1PVY-1xGKPr7Cq2vYvPNrjW_v8ytA_2b3iygikhmMkBPzcBMTxOmEbbt8lj17kBw5Qs1UyrUudpvqaKSwABYk2PP9FlmOKQN5GVULoUICGr01flY0gpYvM-NwW7bsrmpuy6KZubyvz7v399x2_VZHCyAS551zUxV9KmD2fAcGMofwG4ApqA</recordid><startdate>20141209</startdate><enddate>20141209</enddate><creator>NAIDOO, J</creator><creator>PAGE, D. B</creator><creator>WOLCHOK, J. D</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7T5</scope><scope>5PM</scope></search><sort><creationdate>20141209</creationdate><title>Immune modulation for cancer therapy</title><author>NAIDOO, J ; PAGE, D. B ; WOLCHOK, J. D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Biological and medical sciences</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Minireview</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NAIDOO, J</creatorcontrib><creatorcontrib>PAGE, D. B</creatorcontrib><creatorcontrib>WOLCHOK, J. D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NAIDOO, J</au><au>PAGE, D. B</au><au>WOLCHOK, J. D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune modulation for cancer therapy</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>2014-12-09</date><risdate>2014</risdate><volume>111</volume><issue>12</issue><spage>2214</spage><epage>2219</epage><pages>2214-2219</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><notes>ObjectType-Article-1</notes><notes>ObjectType-Feature-2</notes><abstract>Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>25211661</pmid><doi>10.1038/bjc.2014.348</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2014-12, Vol.111 (12), p.2214-2219
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4264429
source PubMed Central
subjects Antibodies
Antigens
Biological and medical sciences
Cancer therapies
Cell death
Cytotoxicity
Drug dosages
Humans
Immunoglobulins
Immunotherapy
Immunotherapy - methods
Ligands
Lymphocytes
Medical sciences
Melanoma
Metastasis
Minireview
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - immunology
Neoplasms - therapy
Peptides
Proteins
Tumor necrosis factor-TNF
Tumors
Vaccines
title Immune modulation for cancer therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T19%3A27%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20modulation%20for%20cancer%20therapy&rft.jtitle=British%20journal%20of%20cancer&rft.au=NAIDOO,%20J&rft.date=2014-12-09&rft.volume=111&rft.issue=12&rft.spage=2214&rft.epage=2219&rft.pages=2214-2219&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2014.348&rft_dat=%3Cproquest_pubme%3E1727687586%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c545t-4f90e3e3dafd6a0e7adfbc2ed4e586a6207f302c7e3c496557b04c33ed944a5b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1646784050&rft_id=info:pmid/25211661&rfr_iscdi=true